## Abstract Antibody to hepatitis B surface antigen (HBsAg) (antiβHBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and antiβHBs (concurrent HBsAg/ antiβHBs) with hepatocellular carcinoma (HCC). The aim of t
The structure of hepatitis B surface antigen and its antigenic sites
β Scribed by Darrell L. Peterson
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 639 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0265-9247
No coin nor oath required. For personal study only.
β¦ Synopsis
Hepatitis B virus infects about 200 million people worldwide yearly. The consequences of the infection range from mild, sew-limiting hepatitis with full recovery and immunity to chronic infection with liver disease of varying severity, including fulminant hepatitis and death. Alternatively, individuals may become healthy carriers of the virus and thus serve as a reservoir of infection. In addition, all chronic carriers of the virus are also at risk for development of primary hepatocellular carcinoma later in life. Eforts to combat this disease on a global scale require an inexpensive vaccine. Studies of the hepatitis B viral coat protein (HBsAg) have permitted the development of two generations of vaccine to date, and detailed structural studies of its antigenic sites may eventually allow the development of a completely synthetic (and therefore inexpensitre) vaccine in the future.
π SIMILAR VOLUMES
The increasing use of hepatitis B vaccination has had an overwhelming positive impact on the prevention of hepatitis B viral infection. Mutations in the hepatitis B surface antigen (HBsAg) gene occur as a result of vaccine escape mutants, anti-hepatitis B surface antigen immunotherapy, or in chronic
Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utilit
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B surface antimonths. 2 From the 415 children, we recruited 16 chronically infected gen antibody; HBV, hepatitis B virus; PCR, polymerase chain reaction; PBMC, peripheral children who had cleared serum HBsAg for more than 2 years
## Abstract Small hepatitis B surface antigen (HBsAg) is considered to be the best marker for the diagnosis of Hepatitis B virus infection. However, HBsAg variants with mutations within the βaβ determinant may be poorly or not detected by diagnostic assays. Three antiβHBsAg monoclonal antibodies (6